Today: 9 June 2026
Suzhou Maxwell Technologies stock price slides 4.7% as insider selling starts; what to watch Monday
1 February 2026
2 mins read

Suzhou Maxwell Technologies stock price slides 4.7% as insider selling starts; what to watch Monday

Shanghai, Feb 1, 2026, 10:02 GMT+8 — Market closed

  • Suzhou Maxwell Technologies’ Class A shares ended Friday at 310.52 yuan, slipping 4.67%.
  • A Shenzhen exchange filing revealed that general manager Wang Zhenggen offloaded 411,500 shares on Jan. 29.
  • Traders are set to monitor further shareholder selling alongside new China factory data in the upcoming session.

Suzhou Maxwell Technologies Co., Ltd.’s Class A shares (300751.SZ) slipped 4.67% to 310.52 yuan on Friday, a late sell-off putting the stock under the microscope ahead of Monday’s session. The firm produces equipment for solar-cell manufacturing and other precision industrial lines.

Mainland markets are closed Sunday. Still, the timing is crucial: the period for a previously flagged stake sale by major shareholders has started, bringing new supply into play just as the stock loses steam.

The move follows a sharp rally earlier this week that triggered a response mandated by the exchange. New economic data also suggest a weaker start to the year in China’s industrial sector. The environment remains challenging for high-beta equipment stocks.

A National Business Daily report, referencing the Shenzhen Stock Exchange website, revealed that director and senior executive Wang Zhenggen offloaded 411,500 shares through an auction on Jan. 29. The shares fetched an average price of 339.94 yuan each, generating roughly 140 million yuan ($20.1 million) in proceeds.

In a filing dated Jan. 7, the company revealed that controlling shareholders Zhou Jian and Wang intend to offload up to 5.4 million shares—about 1.94% of the total share capital, excluding those held in a buyback account—between Jan. 29 and April 28. The move is aimed at meeting their personal funding needs. The filing emphasized this won’t affect the company’s control.

In a separate statement dated Jan. 26, Suzhou Maxwell said its stock showed “abnormal volatility” after moving beyond set thresholds for three sessions. The company said it found no undisclosed major issues that warrant disclosure. It also cautioned investors against chasing the “space photovoltaic” theme. Suzhou Maxwell added it is finalising its 2025 annual accounts and will release a 2025 performance forecast if listing rules require it. Dfcfw PDF

China’s official manufacturing PMI slipped to 49.3 in January, dropping back below the 50 mark that divides expansion from contraction, an official survey showed Saturday. Huo Lihui, a statistician at the National Bureau of Statistics, said some manufacturers “traditionally enter a slow period” in January and demand stayed weak. Nomura’s chief China economist Ting Lu warned Beijing will need “much more” policy support to keep growth above 4.5% this year. Reuters

Traders face a clear dilemma: will insider selling find enough buyers, or will it drag the stock down further when the market reopens? In the first hour, volume and price moves will speak louder than any narrative.

But there’s a catch. Should daily disclosures reveal more share sales, or if the company’s 2025 performance outlook falls short of the hopes stirred by the recent “concept” trade, the stock might find it tough to bounce back.

Monday’s session stands out as the next key catalyst. Investors are also eyeing the private-sector RatingDog PMI factory survey due February 2, a report that could steer sentiment on industrial and equipment shares early in the week.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop
Previous Story

Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop

SSE share price flat at 2,422p as a key trading update looms this week
Next Story

SSE share price flat at 2,422p as a key trading update looms this week

Go toTop